Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 2/20 | 0.54 |
| ▸ | SLC6A3 | Q01959 | 4/20 | 0.51 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.51 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.48 |
| ▸ | CACNA1G | O43497 | 5/20 | 0.44 |
| ▸ | PSEN1 | P49768 | 4/20 | 0.40 |
| ▸ | PSEN2 | P49810 | 4/20 | 0.40 |
| ▸ | APH1B | Q8WW43 | 4/20 | 0.40 |
| ▸ | NCSTN | Q92542 | 4/20 | 0.40 |
| ▸ | APH1A | Q96BI3 | 4/20 | 0.40 |
| ▸ | PSENEN | Q9NZ42 | 4/20 | 0.40 |
| ▸ | CA12 | O43570 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | CA7 | P43166 | 1/20 | 0.39 |
| ▸ | CA9 | Q16790 | 1/20 | 0.39 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1807482 | 0.87 | HSD11B1 (0.51) | HSD11B1SLC6A3SLC6A4SLC6A2CACNA1G | |
| SCHEMBL12653435 | 0.86 | PSEN1 (0.38) | HSD11B1SLC6A3SLC6A4SLC6A2PSEN1 | |
| SCHEMBL12653432 | 0.86 | POLB (0.50) | SLC6A3SLC6A4MEN1ALDH1A1KMT2A | |
| SCHEMBL21131084 | 0.86 | SLC6A4 (0.49) | SLC6A3SLC6A4SLC6A2MEN1ALDH1A1 | |
| SCHEMBL12653437 | 0.85 | SLC6A4 (0.55) | SLC6A3SLC6A4SLC6A2PSEN1PSEN2 | |
| SCHEMBL435013 | 0.83 | HSD11B1 (0.68) | HSD11B1SLC6A3SLC6A4SLC6A2CACNA1G | |
| SCHEMBL12653433 | 0.80 | PSEN1 (0.47) | HSD11B1SLC6A3SLC6A4PSEN1PSEN2 | |
| SCHEMBL12886747 | 0.79 | LMNA (0.44) | MEN1ALDH1A1KMT2A | |
| SCHEMBL12653434 | 0.78 | L3MBTL1 (0.43) | SLC6A3SLC6A4SLC6A2PSEN1PSEN2 | |
| SCHEMBL1806822 | 0.78 | HSD11B1 (0.54) | HSD11B1SLC6A3SLC6A4SLC6A2CACNA1G |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2592071-B1 | Tricyclic heterocyclic compounds | BRISTOL MYERS SQUIBB CO (US) | 2019-09-18 | — | — | EP | disclosed |
| EP-2592071-B1 | Tricyclic heterocyclic compounds | BRISTOL MYERS SQUIBB CO (US) | 2019-09-18 | — | — | EP | disclosed |
| US-9216972-B2 | Tricyclic heterocyclic compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-12-22 | — | — | US | disclosed |
| US-9216972-B2 | Tricyclic heterocyclic compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-12-22 | — | — | US | disclosed |
| US-9216972-B2 | Tricyclic heterocyclic compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-12-22 | — | — | US | disclosed |
| EP-2592071-A1 | Tricyclic heterocyclic compounds | Bristol-Myers Squibb Company (US) | 2013-05-15 | — | — | EP | disclosed |
| EP-2592071-A1 | Tricyclic heterocyclic compounds | Bristol-Myers Squibb Company (US) | 2013-05-15 | — | — | EP | disclosed |
| EP-2493866-A1 | TRICYCLIC HETEROCYCLIC COMPOUNDS | Bristol-Myers Squibb Company (US) | 2012-09-05 | — | — | EP | disclosed |
| US-20120214767-A1 | TRICYCLIC HETEROCYCLIC COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY | 2012-08-23 | — | — | US | disclosed |
| US-20120214767-A1 | TRICYCLIC HETEROCYCLIC COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY | 2012-08-23 | — | — | US | disclosed |
| US-20120214767-A1 | TRICYCLIC HETEROCYCLIC COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY | 2012-08-23 | — | — | US | disclosed |
| WO-2011059784-A1 | TRICYCLIC HETEROCYCLIC COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-05-19 | — | — | WO | disclosed |
| WO-2011059784-A1 | TRICYCLIC HETEROCYCLIC COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-05-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120214767-A1 | TRICYCLIC HETEROCYCLIC COMPOUNDS | S1PR1, S1PR3, TBXA2R | HSD11B1 782/4885SLC6A3 3263/4885SLC6A4 2800/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.